Erasca to Host Conference Call and Webcast to Discuss Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015

Erasca (Nasdaq: ERAS) will host a conference call and live webcast on April 27, 2026 at 4:30 PM ET to discuss preliminary Phase 1 dose-escalation data for its pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors.

Rhea-AI Summary

Erasca (Nasdaq: ERAS) will host a conference call and live webcast on April 27, 2026 at 4:30 PM ET to discuss preliminary Phase 1 dose-escalation data for its pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors.

Investors can join via webcast at Erasca.com/events or by phone (1-877-407-3982 U.S./Canada; 1-201-493-6780 international).

Argus Apr 27 session

-10.89% close to close Open Argus

Details

News Market Reaction – ERAS

In the Apr 27 session, ERAS declined 10.89%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -10.9% in the session following this news. A negative reaction despite a data-focu...

Analysis

The stock dropped -10.9% in the session following this news. A negative reaction despite a data-focused conference call announcement would fit periods where investors reassessed risk around early-stage oncology programs and potential future financing. Prior filings highlighted narrowed 2025 net loss of $124.5M and a substantial $500,000,000 shelf with a $200,000,000 ATM component, so concerns could have centered on dilution or trial uncertainty rather than the logistics of the call itself.

Key Figures

Shelf registration size: $500,000,000 ATM program size: $200,000,000 Cash and securities: $341.8M +5 more

Shelf registration size

$500,000,000

S-3 shelf capacity for multiple security types

ATM program size

$200,000,000

Common stock under at-the-market Sale Agreement with Jefferies LLC

Cash and securities

$341.8M

Cash, cash equivalents, and marketable securities as of 12/31/2025

Pro forma cash

$434M

Expected cash after January 2026 offering, funding operations into H2 2028

Net loss 2025

$124.5M

Full-year 2025 net loss, $(0.44) per share

Net loss 2024

$161.7M

Full-year 2024 net loss, $(0.69) per share

Shares outstanding

310,799,547

Common shares outstanding as of 03/05/2026

Short interest

13.33%

Short interest as percentage of float; days to cover 6.07

Previous Conferences,clinical trial Reports

1 past event · Latest: Sep 25

Same Type 1 event

1. Sep 25

   Conference data preview

   24h Move

   +8.1%

   Announcement of preliminary SEACRAFT-1 Phase 1 data and investor R&D update.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

phase 1, dose escalation, molecular glue, ras/mapk pathway, +1 more

5 terms

phase 1 medical

"to discuss preliminary Phase 1 dose escalation data for its potentially"

Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.

dose escalation medical

"to discuss preliminary Phase 1 dose escalation data for its potentially"

Dose escalation is the process of gradually increasing the amount of a treatment or substance over time. In finance, it can refer to slowly raising investments or commitments to manage risk and assess performance. For investors, understanding dose escalation helps gauge how companies or strategies adjust their approaches, which can impact future growth or stability.

molecular glue medical

"potentially best-in-class pan-RAS molecular glue ERAS-0015 in patients"

A molecular glue is a small synthetic molecule that sticks two proteins together inside a cell so one will be tagged and removed by the cell’s waste-disposal machinery; think of it as a tiny adapter that forces a faulty part onto a conveyor belt for removal. Investors care because this approach can turn previously untreatable disease targets into drug opportunities, creating potential high-value therapies but with scientific and regulatory risk.

ras/mapk pathway medical

"developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers"

A cellular signaling route that acts like a chain of command inside cells to tell them when to grow, divide, or die; when parts of this RAS/MAPK pathway are stuck “on,” it can drive uncontrolled cell growth that leads to cancer. Investors care because drugs, tests, or diagnostics that target or measure this pathway can become valuable products, affect drug approval chances, and change a company’s revenue or risk profile much like fixing a critical production line in a factory.

pan-ras medical

"potentially best-in-class pan-RAS molecular glue ERAS-0015 in patients"

Pan-RAS describes a drug or treatment designed to block all major versions of the RAS family of proteins, which are molecular switches that can drive many types of cancer when they malfunction. For investors, a successful pan-RAS therapy is significant because it could treat a wide range of tumors with a single approach—like fixing a faulty master switch instead of individual lightbulbs—potentially expanding the market opportunity but also carrying high scientific and regulatory risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Conference call and live webcast today at 4:30 PM Eastern Time

SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss preliminary Phase 1 dose escalation data for its potentially best-in-class pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors today, Monday, April 27, 2026, at 4:30 pm ET.

Conference Call and Webcast Information
Erasca will hold a conference call and webcast Monday, April 27, 2026, at 4:30 pm ET. The webcast link for the conference call is here. The dial-in number is 1-877-407-3982 (U.S./Canada) or 1-201-493-6780 (international) or click the Call me™ Link. The live webcast and replay may be accessed by visiting Erasca’s website at Erasca.com/events.

About ERAS-0015
ERAS-0015 is an investigational, oral, highly potent pan-RAS molecular glue designed to inhibit RAS signaling with a potential best-in-class profile. Erasca is evaluating ERAS-0015 in the AURORAS-1 Phase 1 trial in patients with RAS-mutant solid tumors. Early dose escalation data in AURORAS-1 demonstrated favorable safety and tolerability results, well-behaved, linear PK, and confirmed and unconfirmed partial responses in multiple patients across multiple tumor types with different RAS mutations, including confirmed and unconfirmed partial responses at doses as low as 8 mg once daily (QD). ERAS-0015 is also designed to prevent resistance against mutant-selective inhibitors through inhibition of RAS wildtype variants. In addition, ERAS-0015 has demonstrated favorable absorption, distribution, metabolism, and excretion (ADME) and pharmacokinetic (PK) properties in multiple animal species. 

About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.

Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

Source: Erasca, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Erasca (ERAS) discussing ERAS-0015 Phase 1 dose-escalation data?

The call is scheduled for April 27, 2026 at 4:30 PM ET. According to the company, the event covers preliminary Phase 1 dose-escalation results for ERAS-0015 in RAS-mutant solid tumors and will be available via live webcast and replay.

How can investors access the Erasca (ERAS) webcast for the April 27, 2026 event?

Investors can access the live webcast at Erasca.com/events. According to the company, a replay will also be posted there and phone dial-in options are provided for U.S./Canada and international participants.

What will Erasca (ERAS) discuss about ERAS-0015 on the April 27, 2026 call?

Erasca will discuss preliminary Phase 1 dose-escalation data for ERAS-0015 in RAS-mutant solid tumors. According to the company, the focus is on early safety and dosing observations from the dose-escalation portion of the study.

What phone numbers can shareholders use to join the Erasca (ERAS) conference call?

Use 1-877-407-3982 for U.S./Canada or 1-201-493-6780 for international access. According to the company, a Call me™ link is also available to connect participants directly to the conference.

Will Erasca (ERAS) provide a replay of the April 27, 2026 ERAS-0015 webcast?

Yes, a replay will be available on the company website. According to the company, the live webcast and replay can be accessed at Erasca.com/events following the conclusion of the call.